A phase 1 study to evaluate the safety and LDL cholesterol –lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9

ConclusionsOverall, RG7652 elicited substantial and sustained dose‐related LDL‐C reductions with an acceptable safety profile and minimal immunogenicity.
Source: Clinical Cardiology - Category: Cardiology Authors: Tags: CLINICAL INVESTIGATIONS Source Type: research